Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract

Abstract:
PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health.

PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract

Indianapolis, IN | Posted on March 2nd, 2010

The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010. This curative vaccine, which is based on PDS Biotechnology's Versamune™ platform nanotechnology, has demonstrated potent efficacy in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Over 400 million people are infected with the HPV virus and several common cancers are caused by the infection, including cervical, head and neck and anal cancers. No cures exist for these cancers.

The award was based on successful completion of a phase 1 SBIR contract demonstrating efficacy of the drug in human model systems, as well as recent GLP toxicology, pharmacokinetic and bio-distribution studies demonstrating an excellent safety profile and efficient uptake of the drug by the immune system. The new contract will cover over 70% of the costs required to complete the IND-enabling studies. The remaining 30% of the costs will be covered by non-federal government funds.

PDS Biotechnology's Versamune™ nanotechnology platform facilitates efficient uptake of disease-associated proteins and peptides by cells of the immune system and simultaneously acts a strong immune system modulator without the inflammatory side effects induced by current immune stimulators (also known as adjuvants). The result is simple, safe and cost effective drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular disease-related protein formulated with Versamune™. The company's Versamune™-based melanoma product has also demonstrated high efficacy in curing melanoma, which is the most aggressive form of skin cancer, in preclinical animal studies.

This project is funded in part or in whole with Federal Funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN261200900082C. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based biotechnology company applying the company's proprietary Versamune™ platform to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
500 Industrial Drive
Suite A
Lawrenceburg, IN 47025
Tel: 812-537-0779
Fax: 812-537-1614

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

IDTechEx Printed Electronics Europe 2014 Award Winners April 1st, 2014

Dais Analytic Wins SBIR Grant: Dais Analytic Receives US Army Small Business Innovation Research Grant to Further Its Demonstrated Successes in Cleaning Most Forms of Wastewater March 28th, 2014

Nanobiotechnology

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014

Biologists Develop Nanosensors to Visualize Movements and Distribution of Plant Stress Hormone April 15th, 2014

In latest generation of tiny biosensors, size isn't everything: UCLA researchers overturn conventional wisdom on nanowire-based diagnostic devices April 11th, 2014

New-Contracts/Sales/Customers

Industrial Nanotech, Inc. Lands First Major Order from Pemex, Mexico’s State-Owned Oil and Gas Company April 14th, 2014

TED Selects Nanotech for Branding and Security on 30th Anniversary Conferences: Nanotech and TED collaborate to create a custom security feature using nano-imaging March 17th, 2014

Simon Fraser University Completes Installation of Electron Microscopes from FEI: SFU’s new multi-million-dollar Centre for Soft Materials now offers the most advanced suite of microscopes in Western Canada March 11th, 2014

Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520 March 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE